Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198484 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Vitrase as a Spreading Agent
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT00198484: Completed Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT00198484 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 108 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00198484, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
Primary Outcome
Physician evaluation of effectiveness of Vitrase as an adjuvant and overall satisfaction, via questionnaire;
Interventions
- DRUG Vitrase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
What the finished NCT00198484 record still lists
NCT00198484 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Vitrase is the first listed.
NCT00198484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00198484 about?
NCT00198484 is a clinical study titled "Evaluation of Vitrase as a Spreading Agent". The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
What is the current status of trial NCT00198484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2004-10. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00198484?
The interventions under investigation include: Vitrase (DRUG).
Who is sponsoring clinical trial NCT00198484?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00198484's enrollment target sits among peer trials
108 1664th of 2000 higher than 335 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia